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Lycopene rich food and dark chocolate are among the best-documented products with a broad health benefit. This study explored
the systemic effect of lycopene and dark chocolate (DC) on gut microbiota, blood, liver metabolism, skeletal muscle tissue
oxygenation and skin. 30 volunteers were recruited for this trial, 15 women and 15 men with a mean age of 55 ± 5.7 years and with
moderate obesity, 30 < BMI < 35 kg/m2. They were randomized and divided into five equal interventional groups: three received
different formulations of lycopene, one of them with a 7mg daily dose and two with 30mg; another group was given 10 g of DC
with 7mg lycopene embedded into its matrix, and the last group received 10 g DC. The trial was double-blinded for the three
lycopene groups and separately for the 2 DC groups; the trial lasted for 1 month. By the end of the trial there were dose-dependent
changes in the gut microbiota profile in all three lycopene groups with an increase of relative abundance of, e.g., Biﬁdobacterium
adolescentis and Biﬁdobacterium longum. This was also accompanied by dose-dependent changes in the blood, liver metabolism,
skeletal muscle and skin parameters. Consumption of DC resulted in increased relative abundance of, e.g., Lactobacillus and a
reduction of corneocyte exfoliation. This is the first study which reports the prebiotic potential of lycopene and DC.
1. Introduction
Carotenoids are essential micronutrients, which cannot be
synthesized by humans and must be obtained from food.
Lycopene, the red pigment of tomatoes, watermelon, and
some other fruits, is one major carotenoids. Intake of
lycopene rich food has been linked to lower prevalence of
cardiovascular disease, stroke [1] and some forms of cancer
[2, 3]. Limited interventional clinical studies have indicated
its therapeutic ability to slow down development of carotid
atherosclerosis [4], anti-infective and anti-inflammatory
properties [5], improvement of parameters associated with
prostate hyperplasia [6], benefit in management of prostate
cancer [7] and help to protect skin from UV damage
[8, 9].
The concentration of lycopene in blood and body tissues
is highly variable and depends on dietary habits and age and
has also been related to health status. For example, the plasma
or serum concentration could vary from about 60 ng/ml, or
below, to 600 ng/ml or above [10]. A reduced level in the body
could be due to three major reasons: either low dietary intake,
impaired lycopene absorption and processing for example
in older persons or those with metabolic syndrome, which
results in poor bioavailability of this carotenoid or due to
its accelerated depletion as a result of ongoing free radical
pathologies in the body.
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The current consensus on the broad beneficial effects of
lycopene on health exists with regard to its powerful antioxi-
dant properties and the related protection of lipoproteins and
other lipid structures from oxidative damage, which typically
are associated with a number of pathological conditions [1,
11].
It has been demonstrated that cocoa flavanols have a
systemic effect in healthy volunteers with prebiotic activity
on the gut microbiome and reduction of blood lipoproteins
produced by the liver [12]. However, in real life these flavanols
usually consumed by humans in a food form of choco-
late, which contains cocoa butter, triglyceride lipids, other
cocoa ingredients, and cocobiota metabolites [13]. Therefore,
another objective of our study was to assess whether regular
consumption of dark chocolate, DC, would have a similar
effect as the cocoa flavanols drink. Although there were a
number of reports, which demonstrated a positive impact of
DC on blood lipids [14, 15], to the best of our knowledge this
is the first study investigating the effect of lycopene and DC
on the gut microbiota inmiddle-aged subjects with moderate
obesity, 30 < Body Mass Index, BMI < 35 kg/m2. For this
purpose we used GA lycopene, which is specifically formu-
lated to overcome reduced bioavailability of this carotenoid
in older people and in individuals with metabolic syndrome
(Lycotec, UK). We found that continuous administration of
this product for 4 weeks resulted in significant prebiotic
effects. These positive changes in the gut microbiota profile
were accompanied by systemic improvement of different
physiological parameters of the participants from blood and
liver metabolism to peripheral tissues including skin.
2. Methods
Study Design. In total 30 volunteers were recruited to take
part in the study, 15 male and 15 female, all Caucasian within
the age span of 40–68 and median 55 ± 5.7 years. They
were randomized and divided into five groups of equal size.
Group I received a daily dose of 10 g dark chocolate with
7mg lycopene by a proprietary protocol guaranteeing its
maximum embedment into the lipid part of the chocolate, L-
Tug, and on another optimal lycopene coating of chocolate
crystals and formation of coco- lycosomes, DCL [16]. Group
II received daily one capsule of 7mg GA lycopene formulated
with medium saturated fatty acids, GAL-MSFA, Group III
one capsule daily of 30mg GAL-MSFA, group IV one capsule
daily 30mg of GA lycopene formulated with polyunsaturated
fatty acids, GAL-PUFA, and group V 10 g of the control dark
chocolate daily. Three GAL groups received blinded lycopene
capsules, as two other groups received blinded DC products.
Products. All products for the trial were developed and made
by Lycotec Ltd. (Cambridge, United Kingdom). The product
was especially designed to improve lycopene bioavailability
in middle-aged persons, 50 years old or above, or in those
who have such conditions as metabolic syndrome, fatty liver,
etc. [17]. It contained phosphatidylcholine, which serves as a
principle scaffolding element for incorporation of lycopene
during lipoprotein intracellular reassembly, the process that
is essential for lycopene transportation but impaired in the
above individuals.
There were two formulations of GAL, for two different
nutraceutical applications, which were applied in this study.
The first was with a blend of MSFA to facilitate formation of
small-medium chylomicrons, whichwould be transported by
the portal vein for liver targeting delivery of lycopene. The
second one was a blend with PUFA to facilitate formation
of larger chylomicrons, which would be transported by the
thoracic duct for the systemic blood circulation bypassing the
liver. All GAL products were made in gelatin capsule.
For the control DC and DCL Green & Black’s 70%
dark chocolate was used. It was made from Trinitario cocoa
beans and contained 42% fat, of which saturates were 25%;
carbohydrates 36.5%, of which sugars were 28.5%; fibre 10%,
protein 9.1%, salt 0.13%. Each 10 g bar contained 1.5mg of
catechins, 6.6mg of epicatechins, 1.9mg of dimer-B2, 7.5mg
of caffeine, 75mg of theobromine, 75𝜇g of phenylethylamine,
55𝜇g of serotonin, and ≤ 0.1𝜇g of resveratrol.
Both capsule and chocolate products were advised to be
taken once a day after the main meal.
The duration of the trial was 1 month.
The treatment part of the study and the blood analysis
were conducted at the Institute of Cardiology, the Min-
istry of Health of the Russian Federation (Saratov, Russian
Federation) by Lycotec Ltd. (Cambridge, United Kingdom).
The protocol was approved by the Local Ethics Committee
(FGBU SarNIIK18.02.2014). Trial registration number was
ACTRN12618000715279. All patients were informed of the
purpose and goals of the study and had signed a consent form
before enrolment and participation in the study.
The stool microbiota analysis was made by the Depart-
ment of Food Science in the Section of FoodMicrobiology, at
the University of Copenhagen in Denmark.
The skin samples were analysed by Lycotec in Cambridge.
2.1. Inclusion/Exclusion Criteria
Inclusion Criteria were as follows:
(i) ability to sign an informed consent,
(ii) nonsmokers or light-to-moderate smokers (≤10
cigarettes daily),
(iii) moderately obesewith BMI between 30 and 35 kg/m2,
(iv) with elevated serum markers of inflammatory oxida-
tive damage, IOD ≥ 40 𝜇M/mL and oxidative stress,
LDL-Px, ELISA × 103 ≥ 200,
(v) no participation in other dietary trials during the last
3 months before enrolment and duration of study,
(vi) willingness and ability to comply with the study
protocol for the duration of the study.
Exclusion criteria were as follows:
(i) unwillingness to sign informed consent,
(ii) unable to comply with the protocol for the duration
of the study,
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(iii) history of myocardial infarction in the 3 months
preceding the study, ejection fraction (EF) < 45%,
(iv) significant medical condition that would impact
safety considerations (e.g., significantly elevated liver
enzymes, hepatitis, severe dermatitis, uncontrolled
diabetes, cancer, severeGI disease, fibromyalgia, renal
failure, recent CVA (cerebrovascular accident), pan-
creatitis, respiratory diseases, epilepsy, etc.),
(v) compulsive alcohol abuse (>10 drinks weekly),
(vi) or regular exposure to other substances of abuse,
(vii) participation in other nutritional or pharmaceutical
studies,
(viii) resting heart rate of >100 beats per minute or <50
beats per minute,
(ix) positive test for tuberculosis, HIV, or hepatitis B,
(x) inability to tolerate phlebotomy,
(xi) special diets in the 4 weeks prior to the study (e.g.,
liquid, protein, and raw food diet),
(xii) tomato or DC intolerance.
2.2. BMI, Pulse Rate, and Systolic andDiastolic Blood Pressure.
Measurements of body mass index, BMI, body mass of the
patients and their height were carried out in the morning and
BMIwas calculated in kg/m2. Pulse rate, systolic and diastolic
blood pressure, SBP, and DBP were recorded three times on
the left arm of the seated patient after 15min of rest. The
time between measurements was greater than 2 minutes. The
mean result for each parameter was calculated. All body and
vascular parameters were recorded in the morning between
8 and 10 am.
Tissue Oxygenation. Thenar eminence and forearm muscles
of the patients were used as a tissue target for the assessment
of oxygen saturation, StO
2
, or combined level of oxygenated
haemoglobin and myoglobin. StO
2
was assessed by continu-
ous wavelength near-infrared spectroscopy, NIRS, with wide-
gap second-derivative (In Spectra, Hutchinson Technology,
MN, USA). The measurements were taken at different time
points. The recording was initiated after 15min of rest in a
supine position before occlusion of the brachial artery. It was
then continued during stagnant ischemia induced by rapidly
inflating the cuff to 50mmHg above systolic BP.The ischemia
lasted for 3min, and the recording period lasted for another
5min after that until StO
2
was stabilized. The area under
the hyperaemic curve, AUC, of the recorded signal for the
settling time in the postocclusion period was then calculated
as described earlier in % O
2
/minute [17, 18].
Samples Collection. Blood was collected by phlebotomy in the
morning, in the hospital, and from the arm veins of patients
following night fast.The serumwas separated from the rest of
the clotted mass by centrifugation; aliquots were then stored
in code-labeled tubes for blinded analysis and stored at−80∘C
until use.
For sample collection from the surface of the facial skin
and samples of the cerumen all study participants were
requested to avoid facial and ear hygienic manipulations
for 24 hours before sampling, which was carried out in
the morning in parallel with blood sample collection. Skin
surface sample collection and preparation were performed
as previously described [19]. Briefly, samples were collected
using polyester swabs from the surface of the facial skin (the
sides of the nose). During the procedure two samples were
taken (one swab per side). Each collected sample was placed
on the surface of a microscope slide. A second microscope
slide was pressed against the surface of the first one. This
procedure provided a pair of identical smears. All slides with
collected samples were coded to provide sample anonymity
for blinded analysis and stored at−20∘Cuntil further analysis.
The stool samples were collected either on themorning or
night before the day of the visit to the hospital. Participants
did this collection themselves, at the convenience of their
home, in the morning on the day of visiting clinic. A special
kit and sample containers were provided by the trial team.
The collected samples were labeled and stored at −80∘C until
analysis.
2.3. Gut Microbiome Analysis
2.3.1. DNA Extraction. Genomic DNA was extracted from
200mg stomached fecal material (stomacher 2x 60 sec
at mid speed) using the Power Soil Kit protocol (MoBio
Laboratories).TheFastPrep bead-beating stepwas performed
in 3 cycles of 15 s each at a speed of 6.5M/s in a FastPrep-
24TM Homogenizer (MP). DNA quantity and quality were
measured using a NanoDrop 1000 (Thermo Scientific),
16S rRNA gene library preparation. The fecal microbiota
composition was determined using tag-encoded 16S rRNA
gene MiSeq-based (Illumina, CA, USA) high throughput
sequencing. In brief the V3 region of the 16S rRNA gene was
amplified using primers compatible with the Nextera Index
Kit (Illumina) NXt 338 F:5󸀠- TCGTCGGCAGCGTCAGAT-
GTGTATAAGAGACAGACWCCTACGGGWGGCAGCAG
-3󸀠 and NXt 518 R: 5󸀠- GTCTCGTGGGCTCGGAGATGT-
GTATAAGAGACAGATTACCGCGGCTGCTGG -3󸀠.. [20];
the PCR reactions and library preparation were conducted
as described in [21].
2.3.2. High throughput Sequencing and Data Treatment.
The raw dataset containing pair-ended reads with corre-
sponding quality scores were merged and trimmed using
fastq mergepairs and fastq filter scripts implemented in the
UPARSE pipeline. The minimum overlap length was set to
10 base pairs (bp). The minimum length of merged reads
was 150 bp, the maximum expected error E was 2.0, and
the first truncating position with a quality score was N≤4.
Purging the dataset from chimeric reads and constructing de
novo Operational Taxonomic Units (OTU) was conducted
using the UPARSE pipeline [22]. The Green Genes (13.8)
16S rRNA gene collection was used as a reference database
[23]. Quantitative Insight Into Microbial Ecology (QIIME)
open source software [24] (1.7.0 and 1.8.0) was used for
the subsequent analysis steps. Principal coordinate analy-
sis (PCoA) plots were generated with the Jackknifed Beta
Diversity workflow based on 10 UniFrac distance metrics
4 BioMed Research International
calculated using 10 subsampled OTU tables. The number of
sequences taken for each jackknife subset was set to 90%
of the sequence number within the most indigent sample,
hence 10000 reads per sample. Permutational Multivariate
Analysis of Variance (PERMANOVA) was used to evaluate
group differences using weighted, unweighted, and general-
ized UniFrac distance metrics that were generated based on
rarefied (10000 reads/sample) OTU tables. The relative dis-
tribution of the genera registered was calculated for unified
and summarized in genus level OTU tables. Alpha diversity
measures expressed as observed species values (sequence
similarity 97%) were computed for rarefied OTU tables
(10000 reads/sample) using the alpha rarefaction workflow.
Differences in alpha diversity were determined using a t-
test-based approach employing the nonparametric (Monte
Carlo) method (999 permutations) implemented in the com-
parative alpha diversity workflow. The ANOVA determined
significance of quantitative (relative abundance) association
of OTUs with given categories; p values were False Discovery
Rate (FDR) corrected. These were calculated based on 1000
subsampled OTU tables rarefied to an equal number of reads
(10000 reads/sample). Spearman correlations between the
taxa relative abundance (at the OTU level and summarized
to the species level) and the host parameters were conducted
using observation metadata correlations script (Qiime 1.9.1).
Fisher z-transformation method with 1000 permutations was
used for calculating p values. The influence of explanatory
variables (host parameters) and OTUs relative abundance
(species level) was tested with the rda function (vegan R-
package), using the ANOVA-like permutation tests (1,000) to
determine the significance of the putative constrains effects
[25].
Biochemistry. Glucose, total cholesterol, triglycerides, high
density cholesterol, low density cholesterol and C-reactive
protein were determined using commercially available ana-
lytical kits according to the manufacturers’ instructions
(ByoSystems, R&D Systems).
Lycopene Quantitative Analysis. The lycopene concentration
in all serum samples was measured in duplicate by high-
performance liquid chromatography [26] withmodifications.
Briefly, 400 𝜇l of serum wasmixed with 400𝜇l of ethanol and
was extracted twice with 2ml hexane. The combined hexane
layers were evaporated to dryness in a vacuum (Scan Speed 32
centrifuge) and the residue reconstituted to a volume of 100 𝜇l
in sample solution (absolute ethanol – methylene chloride,
5:1, v/v). The specimens were centrifuged again (15 minutes
at 10,000 g) and clear supernatant was transferred to HPLC
vials. Five microliters of the extract was injected into an
Acquity HSS T3 75x 2.1mm 1.8𝜇m column (Waters, USA)
preceded by a Acquity HSS T3 1.8𝜇m VanGuard precolumn
(Waters, USA) and eluted isocratically at 45∘b with the
mobile phase (acetonitrile – 0.08% phosphoric acid solution
- tert-Butyl methyl ether, 70:5:25, v/v/v) at a flow rate of
0.5ml/min. The lycopene peak was detected by a Photodiode
Array Detector (Waters, USA) at 474 nm. The peak area
was measured using Empower 3 software (Waters, MA). The
lycopene concentration in serum samples was calculated by
reference to an analytical standard (lycopene from tomato,
L9879, Sigma, USA).
Inﬂammatory Oxidative Damage (IOD). Serum samples were
incubated in 0.05M PBS acetate buffer (pH 5.6) overnight,
to imitate the type of oxidative damage which occurs during
the release of lysosomes following neutrophil degranulation.
The following morning the reaction was stopped using
trichloroacetic acid. The concentration of the end products
such as malondialdehyde (MDA), and other possible thiobar-
bituric acid reactive substances (TBARS), was then measured
by colorimetry [27] using reagents and kits from Cayman
Chemical (MC, USA).
LDL-Px and Lipoprotein O
2
. Activity of serum LDL peroxi-
dase proteins, which include IgG with superoxide dismutase
activity, was measured as described previously [28]. Plasma
oxygen, which carried by blood lipids/lipoproteins, was
measured by catalymetry [29].
Statistics. For the assessment of normally distributed param-
eters the Shapiro-Wilk method was used. Student’s t-test
was then applied for both paired and unpaired samples.
In cases where parameters were not normally distributed
the Mann–Whitney test and Kruskal-Wallis test were used.
ANOVA and ANCOVA were used with post hoc analy-
sis (Statistica 9 suite, StatSoft, Inc.). Statistical significance
between two-tailed parameters was considered to be P<0.05.
3. Results
Baseline characteristics of the participants are presented in
Table 1 and were comparable between all five groups.
3.1. Blood and Liver Metabolism. Ingestion of lycopene prod-
ucts for one month, either in the capsule format or in the
chocolate matrix, resulted in a significant increase of its
concentration both in the serum and in the ear skin excretion
(Table 2).
Supplementation with GAL-MSFA resulted in a dose-
dependent significant reduction of markers of oxidative
damage and inflammation. 7mg of lycopene was able to
reduce IOD and LDL-Px, by the end of the month, by 49
𝜇M MDA, or by 35%, and by 200 ELISA units, or by 36%,
while 30mg reduced these parameters by 69, or by 60%,
and 285, by 43%, accordingly. 30mg of GAL-MSFA was 3
fold more effective in inhibiting IOD than the same dose
of lycopene but in the GAL-PUFA formulation. This may
potentially indicate on the liver origin of this blood marker.
Effect of two formulations of lycopene on LDL-Pxwas similar
(Table 2).
DC with or without lycopene had a similar effect on the
inhibition of IOD as 7mg of lycopene. Although both choco-
late products were able to reduce LDL-Px, their effectiveness
was below that of lycopene itself.
Administration of either formulation ofGAL, or lycopene
with DC complex, resulted in significant changes in the
profile of fasting lipoproteins, which are assembled and pro-
duced by the liver. GAL-MSFA reduced in a dose-dependent
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Table 1: Baseline values.
BASELINE CHARACTERISTICS OF THE ENROLLED VOLUNTEERS(Mean +/- SD)
Groups
I II III IV V
Number of Patients 6 6 6 6 6
Males 3 2 4 3 3
Females 3 4 2 3 3
Age 61.8±5.9 56.2±5.9 56.1±5.8 52.1±5.1 63.2±6.1
Light/Moderate Smokers 1 1 1 1 1
Body Mass Index in kg/m2 32.1±2.4 32.7±3.3 33.8±3.5 31.1±3.2 31.8±2.9
Fasting Glucose mmol/dL 6.1±0.42 6.0±0.45 5.7±0.49 5.4±0.43 5.5±0.56
Total Cholesterol mg/dL 185 ± 14.3 181 ± 15.2 175 ± 14.7 187 ± 16.2 180 ± 13.9
Triglycerides mg/dl 135±14.9 136±13.8 136±13.8 127±13.1 122±13.5
LDL mg/dL 144±11.8 143±12.7 121±12.2 137±13.6 131±12.1
HDL mg/dL 41.9±3.2 46.5±4.4 51.2±4.7 49.8±4.4 44.0±4.4
Pulse rate per min 66.7±4.2 67.7±3.5 65.2±3.4 70.5±3.9 66.6±5.1
Blood Pressure
Systolic 112±5.5 123±7.4 117±6.9 124±8.5 118±6.7
Diastolic 77.6±4.4 78.7±5.0 77.6±4.4 76.7±4.6 79±5.6
manner both LDL concentration and triglycerides. This liver
targeting formulation of lycopene, in 30mg dose, was able
to reduce the first parameter by 17mg/dL and the second
by 18mg/dL. Supplementation with GAL-PUFA resulted in
LDL reduction by 13mg/dL and triglycerides by only 3 mg/dL.
Lycopene in the L-Tug complex with dark chocolate was also
able to reduce LDL; however, changes caused by the ingestion
of the control DC were not significant (Table 2).
By the end of the trial there were no changes in the serum
concentration of HDL, glucose and liver enzymes, ALT and
AST (results are not presented).
There were noticeable improvements in the molecular
oxygen metabolism in all groups. In groups supplemented
with GAL-MSFA O
2
concentration and its transportation by
blood lipoproteins was significantly increased by 18-19%, p <
0.05. In the group that received GAL-PUFA this increase was
lower, by 12%, p > 0.05. In the group, which received control
DC, the increase in the lipoprotein O
2
was the highest, by
44%, p <0.01.
These changes in the plasma oxygen transportation trans-
lated to benefit for peripheral tissue oxygenation but not in
the control DC group. Ingestion of all lycopene products also
resulted in a significant boost of tissue oxygenation in skele-
tal muscles. Administration of GAL-MSFA demonstrated a
dose-dependent effect in changes of this parameter. However,
30mg of lycopene in GAL-PUFA formulation was 25%, p
<0.05, more effective than the same dose of lycopene but in
the GAL-MSFA formulation (Table 2).
3.2. Skin Parameters. Supplementation of the participants
with all formulations of lycopene for one month resulted
in significant reversal of age-associated parameters of
sebum and corneocytes. Also for the GAL-PUFA a reduc-
tion was observed, though statistically not significant. The
GAL-PUFA formulation was more effective in improving
cellular parameters of the skin, while GAL-MSFA was more
effective for sebum parameters.
However, different to the blood parameters, observed
changes in the skin, apart from those related to the sebum,
did not have dose-dependency. This may indicate that even
the dose of 7mg of daily supplementation with lycopene was
sufficient to reach its saturated level in this tissue by the end
of the trial.
The viscosity of the sebum, in terms of the size of the lipid
droplets collected from the surface of the skin, was increased
on average by 390 nm during this trial after supplementation
by all formulations of lycopene. However, GAL-PUFA only
slightly increased the diameter of the droplets, by 50 nm,
while GAL-MSFA was much more effective and did it in a
dose-dependent manner, by 180 nm for 7mg of lycopene and
by 480 nm for 30mg (Table 3 and Figure 1 top images).
The rate of corneocyte exfoliation was reduced by about
23% for the former formulation and by 9-11% for the latter.
Moreover, not just the rate of exfoliation was reduced by
lycopene supplementation but also the damage of these cells
too. The number of the clusters of cross-linked corneo-
cytes was reduced by 36% for GAL-PUFA and by 29 to
47% by GAL-MSFA (Table 3 and Figure 1, images in the
middle).
It was interesting to observe that these improvements of
the sebum (Figure 1(a)) and corneocyte (Figure 1(b)) param-
eters were accompanied by significant reduction of the total
load of the gram-negative bacteria on the surface of the skin,
but only by supplementation with GAL-MSFA. In the group
ofGAL-PUFA therewas a similar trend, but it was statistically
insignificant.
In the control DC group the sebum and corneocytes
parameters by the end of the trial were not affected.
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Table 3: Changes in sebum, and corneocyte parameters of the skin after supplementation with GA lycopene for one month.
Parameters before and after 4 weeks of
trial
Groups with GA Lycopene supplementation
I II III IV V
Sebum droplet size, in 𝜇m
before 4.6 ± 1.11 3.96 ± 0.17 3.72 ± 0.43 3.89 ± 0.21 4.9 ± 0.53
after 5.1 ± 0.75∗ 4.14 ± 0.11∗ 4.20 ± 0.88∗ 3.94 ± 0.22 4.9 ± 0.57
Corneocyte exfoliation rate§
before 66 ± 6.8 82 ± 7.8 83 ± 9.3 87 ± 9.5 61 ± 6.2
after 63 ± 6.2 73 ± 12.0∗ 76 ± 7.7∗ 67 ± 13.5∗ 60 ± 6.9
Corneocyte damage§§
before 4.2 ± 0.98 7.19 ± 2.47 3.40 ± 0.97 3.50 ± 1.16 2.0 ± 1.98
after 2.5 ± 0.43∗ 3.80 ± 1.23∗∗ 2.41 ± 0.76∗ 2.17 ± 0.52∗ 1.8 ± 1.23
∗ p < 0.05, ∗∗p < 0.001.
§as an average number of single corneocytes in stratum cornea, §§as an average number of cross-linked damaged corneocyte clusters in stratum cornea; each
parameter was calculated in 40 randomly selected microscopic areas (x 1,000).
Before Aer
(a) Sebum
Before Aer
(b) Exfoliated corneocytes
Figure 1: Changes in skin parameters after supplementation with
7mg of GA lycopene for one month. Typical skin smear samples:
lipid droplets of the sebum were stained with Oil Red O, and
corneocytes with hematoxylin, eosin at 1,000×magnification.
3.3. Gut Microbiome. After 4 weeks of supplementation with
GA lycopene, a shift in the gut microbial communities
was detected in the stool of the participants. The relative
abundance of OTUs on Phyla level changed to increased rel-
ative abundance in Actinobacteria in all intervention groups,
Group IV (30mg lycopene liver targeting) 4.5%- 7.12%, Group
II (7mg lycopene capsule) 2.52%- 2.85%, and a signifi-
cant increase was detected for Group III (30mg lycopene
cardiovascular targeting) with 1.12%- 3.22% p=0.04 (FDR
corrected)(Figure 2). The separation between the week zero
and week 4 of the intervention Group III is also shown in
Figure 2; PERMANOVA analysis indicated a separation R=
0.250, p=0.04)
An increased dose of lycopene 30mg Group III and IV
versus Group II, 7mg, was also reflected in an increased
relative abundance of Actinobacteria (+2.6 Group IV, Group
III +2.1%, Group II +0.33%). Bacteroidetes decreased in the
relative abundance in all groups even though not being sta-
tistically significant (Group IV 4.92%-2.72%,Group III 12.4%
to 7.2%, Group II 31.3% to 21.1%), p >0.5 (FDR corrected).
No significant changes were detected for the remaining GM
composition on Phyla level.
Relative abundances on the OTU species level at week 0
and week 4 for the GAL intervention groups (Group II, III,
IV) with regard to formulations and dose effect are shown in
Table 4.
It is evident that three different OTUs (species level
cut-off), namely, OTUs representing Bifidobacterium species
increased in relative abundance; these were Bifidobacterium
longum, B. adolescentis, and an assigned species.
Whereas several OTUs belonging to the Prevotella genera
had decreased in relative abundance over the course of
the intervention, the statistically insignificant decrease in
Bacteroidetes by GAL formulations seems hence to be genera
specific (Table 4).
Looking at Groups I, II, and V the DC and DC-GAL
(7mg) and GAL-MSFA (7mg) on the Phyla level we have
detected a decreased relative abundance of Actinobacteria
4.4-3.4%, though not statistically significant (p>0.9) for the
DC intervention; no significant changes were detected in the
relative abundance of Bacteroidetes 6.4%-6.3%, Proteobacte-
ria 6.6 -2.4% (p>0.9) for this intervention group after 4 weeks
of DC intervention.
Whereas the relative abundance of Actinobacteria
increased in the DC-GAL group (I) from 1.9% to 3.3% after
4 weeks of intervention, Bacteroidetes on the other hand
increased slightly from 23.4 to 25.8%, Firmicutes decreased
71.7-67.8%, Proteobacteria decreased from 0.49 to 0.24%,
p>0.4; these changes were not statistically significant. The
relative abundance of bacteria on the species level of
the DC intervention and 7mg GAL-DC versus GAL-
MSFA formulations can be seen in Table 5. For the DC
intervention we detected a decrease in OTUs belonging to
8 BioMed Research International
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
DC_0
DC_4
7mgDCL_0
7mgDCL_4
7mg_GAL_MSFA_0
7mg_GAL_MSFA_4
30mg_GAL_PUFA_0
30mg_GAL_PUFA_4
30mgGAL_MSFA_0
30mgGAL_MSFA_4
GUT MICROBIOME CHANGES
TM7
Verrucomicrobia
Tenericutes
Actinobacteria
Proteobacteria
Firmicutes
Bacteroidetes
Figure 2: Bacterial relative abundance (Phylum level) of the different intervention groups before and after the 4 weeks of intervention as
determined by 16S rRNA gene amplicon sequencing. (Group I) fortified with 7mg lycopene - 10 g dark chocolate 7mg DCL, (Group II) 7mg
of lycopene in a capsule 7mg GAL-MSFA, (Group III) 30mg of lycopene in cardiovascular GAL-MSFA, (Group IV) 30mg lycopene liver
targeting/liver health GAL-PUFA. (Group V) 10 g of dark chocolate DC.
the Actinobacteria and an increase in Lactobacillus genera,
though not statistically significant p>0.1.
There were no significant correlations between the tested
parameters and taxa relative abundance (raw OTU level nor
summarized to the species level). No relationship between
the bacterial relative abundance and host parameters could
be found using the redundancy analysis (Figure 3).
4. Discussion
Interconnection between intestine and its flora, liver metabo-
lism and the skin is the subject of intensive investigations [30,
31]. Therefore, in order to correct parameters of one of these
organs, it is important to assess possible changes, which may
develop in parallel in others. However, this alteration may not
be noticeable or be minimal, and ultimately a correction will
not be needed, if targeted persons are healthy and analysed
parameters are within their healthy norm. Therefore, in our
study we have includedmiddle-age subjects with amild form
of obesity with blood markers of subclinical inflammation
and oxidative damage.
Development of metabolic syndrome, age associated
skeletal muscle loss and frailty are accompanied by ongo-
ing, often at a subclinical level, processes of inflammatory
and oxidative damage, which may lead to changes in liver
metabolism, vascular functions, increased body mass and
development of subclinical systemic tissue hypoxia [32,
33]. In our study we observed that supplementation with
lycopene, especially formulated for effective bioavailability, in
PCoA score plot of tag-encoded 16S rRNA
PC
1 
(1
4%
)
PC1 (35%)
Figure 3: PCoA score plot of tag-encoded 16S rRNA gene amplicon
sequencing data based on generalized UniFrac distance metrics (n
= 6, for each time point) of week 0 (red dots) and week 4 (blue dots)
intervention Group III. R = 0.250, p=0.04.
middle-aged people, had antioxidant, anti-inflammatory, and
blood lipid-lowering effects, which are in accordance with
earlier reports [34].These changes in the blood markers were
accompanied by or maybe resulting in the improvement of
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the peripheral tissue StO
2
. The main contributor into this
parameter is the skeletal muscle respiration, although skin
oxygenation is part of it too.
It was observed that supplementation with lycopene can
increase its level in the skin tissue, which results in improving
its protection from UV damage [9]. However, the fact that
lycopene can be secreted to the surface of the human body
either with the cerumen, which we are reporting here, or
sebum (results not shown), to the best of our knowledge, has
not been reported earlier.
Sebum is not only essential for skin lubrication, which
prevents it from dehydration, but is also an important part
of its immune system and its antibacterial acid mantle.
The sebum is also supplying antioxidants and perhaps
other beneficial molecules to the surface of the skin [35]. It
has been reported that with ageing the quality of the sebum is
impaired, and in particular its viscosity, is increased, which is
accompanied by accelerated corneocyte desquamation [19].
In our study we observed that supplementation of the diet
with lycopene of middle-aged persons resulted in the restora-
tion of the sebum viscosity, reduction of the corneocyte
damage, and desquamation.
Continuous ingestion of DC had also a significant pos-
itive effect on liver associated markers of IOD and LDL-
Px and also on the concentration of lipoprotein transported
O
2
. However, these positive changes were not translated in
improvement of skeletal muscle respiration and analysed skin
parameters.
The absence of any direct correlations between relative
abundance of gut taxa and analysed parameters of the blood,
skeletal muscle and skin indicates a complex intertwined
relationship between gut microbiome environment and the
host metabolic pathways.
Prebiotics are traditionally considered to be non-
digestable food ingredients, which can reach the intestine
and be selectively utilized by hostmicroorganisms conferring
a health benefit [36, 37].
There are a number of molecules within food, which are
not fully digestible; hence, they can reach the colon and its
microbiota. Carotenoids and lycopene in particular belong to
these types of partially digestible molecules [38, 39].
In our study we observed that regular intake for one
month middle-aged mildly obese persons of lycopene, either
in the GA formulations or in L-Tug chocolate resulted in
significant changes in the profile of the gut microbiota.
GAL formulations led to a dose-dependent increase
of members of the Phyla Actinobacteria, mainly driven
by an increase in the relative abundance of Biﬁdobacterium
spp. such as B. longum and B. adolescentis, indicating a
prebiotic potential of these formulations. Further, in the
DC intervention we observed an increase in a Lactobacillus
related OTUs indicating a selective prebiotic potential of
DC.
Bifidobacteria are one of the best studied genera of ben-
eficial bacteria and often marketed as probiotics, presumably
conferring a broad range of health benefits not only in the
gut environment but in the whole body. This involves their
ability to control bacterial and viral pathogens, stimulate local
intestinal and systemic immune system, and improve lipid
metabolism and weight management [40, 41]. The loss or
reduction of the bifidobacterial gut associated population
could be a significant factor associatedwith ageing-associated
frailty development [42].
There is emerging evidence that dysbiosis of the gut
microbiome and alteration of the associated bacterial gene
pool and metabolic pathways may contribute to the devel-
opment of pathogenesis of obesity [43–45] although it is still
under debate whether the relative abundance of Bacteroides
within the microbiome has been associated with obesity [46,
47].
In our study we observed that continuous intervention
with GAL, DC, and DCL resulted in significant decrease in
the abundance of Bacteroidetes. This could be explained
either by direct action of this carotenoid, or its indirect
activity via stimulation of some species of Biﬁdobacteria, or
a combination of both factors.
It was interesting that observed lycopene effects on the gut
bacteria, bloodmarkers of inflammation and oxidation, lipids
produced by the liver and by the skin (sebum) and peripheral
tissue oxygenation were all dose-dependent.
This indicates that the observed complex of positive
systemic changes could not only be a result of direct action of
lycopene but also a conseqence of its indirect activity via stim-
ulation of production of signaling metabolites Biﬁdobacteria
adolescentis population with the blood, liver, skeletal; muscles
and skin, which lycopene can control.
Continuous ingestion of the DC resulted in an increase
in the abundance of Lactobacillus spp., which also constitutes
a genus where several strains have been investigated and also
marketed as probiotics. Increased relative abundancewas also
accompanied by reduction of liver associated blood markers
of oxidative damage and inflammation. However, these pos-
itive changes did not positively affect skin parameters in this
study group.
These results raised a number of unanswered questions,
one of them being whether the observed systemic effects are
specific to the lycopene molecule or other carotenoids would
have similar properties.
The other question, to which we do not have an answer,
is whether lycopene or dark chocolate molecules directly
affected growth of the Biﬁdobacteria adolescentis, B. longum,
and Lactobacillus or if it was their indirect effect via systemic
changes. The improvement of metabolism and physiology of
the gut tissues may lead to its better control of the microbiota
and boost the growth of bacteria with proposed health
benefits.
Whatever the nature of the prebiotic effect of lycopene,
this, to the best of our knowledge, is the first report that
ingestion of a carotenoidmay have this new property. It is also
for the first time our study demonstrated that dark chocolate
has a similar effect albeit selective for a different putatively
beneficial bacteria.
To conclude, the observed systemic effect of lycopene
supplementation, or dark chocolate ingestion, which includes
improvement of gut, blood, liver lipid metabolism and, for
the former, skeletal muscles and skin parameters could be
not just due to the carotenoid and dark chocolate prop-
erties themselves, but are likely also to modulate the gut
14 BioMed Research International
microbiome increasing the relative abundance of putatively
beneficial bifidobacteria and lactobacilli.
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